The results in the present study independently predicted that HDACis may be potential drugs for patients with high-RS EGFR-WT NSCLC and implicated the possibility of HDACis as single drugs for lung cancer therapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.